Jim Boulanger, Ph.D.

Coordonnateur scientifique

Jim Boulanger est titulaire d’un baccalauréat en biologie, concentration microbiologie (1998), d’une maîtrise en immunologie (2000) ainsi que d’un doctorat en biologie cellulaire de l’Université de Sherbrooke (2007).

Après avoir été professionnel de recherche pendant trois ans, M. Boulanger a rejoint en 2010 la Direction de la lutte contre le cancer, devenue la Direction générale de cancérologie (DGC), au ministère de la Santé et des Service sociaux (MSSS) en tant que conseiller scientifique. Il a alors participé aux travaux du Comité de l’évolution des pratiques en oncologie (CEPO) ainsi qu’à divers dossiers de la DGC.

C’est en 2013 que M. Boulanger s’est joint à l’Unité d’évaluation en cancérologie de l’INESSS au sein de la Direction des services de santé et de l’évaluation des technologies. Il y assume aujourd’hui les fonctions de coordonnateur de l’Unité.  

 
Date Title
12-19-2025 Douleur chronique - algorithmes de prise en charge
09-29-2025 Access to breast cancer screening for Québec women aged 40 to 49: issues, considerations and implementation approach
08-04-2025 National Medical Protocol - Initiate lung cancer screening using low-dose computed tomography (LDCT) and ensure follow-up
08-04-2025 Tumor Biomarkers Related to the Management of People with Cholangiocarcinoma
01-28-2025 Effectiveness and Safety of Scalp Cooling to Prevent Chemotherapy-Induced Alopecia (CIA)
01-22-2025 Lung cancer – algorithms for diagnosis, treatment and follow-up
01-22-2025 Algorithmes d’investigation, de traitement et de suivi du cancer du sein
09-16-2024 Evaluation of the lung cancer screening pilot project: effects on participants' health and organizational impact on the healthcare system
09-03-2024 Systemic Treatment Algorithm for Metastatic or Advanced Colorectal Cancer, Palliative Intent
08-02-2024 Optimal Modalities for Organizing and Delivering Care and Services Related to Radical Cystectomy in Quebec
07-29-2024 Évaluation initiale de personnes atteintes d’un cancer du poumon et pour qui le premier traitement est la chirurgie – Portrait québécois 2016 – 2019
06-21-2024 Acute myeloid leukemia treatment algorithm
05-17-2024 Breast Cancer Screening with Breast Tomosynthesis
05-13-2024 Cervical cancer screening in Québec: recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test
04-24-2023 Impact of physical activity on the adverse effects of cancer and cancer treatments in adults
03-10-2023 Cryotherapy for the prevention of taxane-induced peripheral neuropathy
07-12-2022 Use of microsurgery for the prevention and treatment of cancer-related lymphedema
06-10-2022 Use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of lung cancer in the Québec context
05-31-2022 High-dose vitamin C injections for cancer patients in Quebec
04-12-2022 Profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic
01-10-2022 Integration of Real-World Data and Evidence into Assessments to Support Decision-Making in the Pharmaceutical Sector
10-25-2021 Creation and characterization of a Québec lung cancer patient cohort using clinical administrative data
08-30-2021 Mammographic density and breast cancer screening
08-17-2021 Relevance of using mpMRI for the diagnostic investigation of prostate cancer mpMRI and prostate cancer diagnosis
01-19-2021 Advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology
01-05-2021 Use of the SpaceOAR™ hydrogel rectal spacer during prostate radiotherapy
01-27-2020 Tomosynthesis and breast cancer: diagnostic evaluation and other uses
09-03-2019 Use of linear accelerators with on-board magnetic resonance imaging (MRI) for real-time MRI-guided radiation therapy treatments
08-15-2019 Axicabtagene ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma
04-23-2019 Pertinence du dépistage du cancer du poumon par la tomographie axiale à faible dose
04-08-2019 Guide de prise en charge de l’extravasation associée aux traitements antinéoplasiques

Subscribe to our newsletter now

Subscription